Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Insulin Lispro 6 Day (6D)
Insulin Lispro 6 Day · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Insulin Lispro 6 Day (6D) | EXPERIMENTAL | - |
| Insulin Aspart 6 Day (6D) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Insulin Lispro 6 Day (6D) | DRUG | Administered by infusion pump for 12 week treatment period |
| Insulin Aspart 6 Day (6D) | DRUG | Administered by infusion pump for 12 week treatment period |
Inclusion Criteria: * Diagnosed with type 1 diabetes (World Health Organization criteria) for at least 24 months * Treated with continuous subcutaneous insulin infusion (CSII) therapy for the previous 6 months * Mean total daily insulin dose for 3 days prior to screening less than or equal to 46 un...
Insulin Lispro 6 Day is an investigational insulin therapy being studied for the treatment of type 1 diabetes mellitus. It is designed for use in insulin pumps, where it is compared with insulin aspart in a six-day pump use setting. It is not yet approved for commercial use.
Insulin Lispro 6 Day works as an agonist of the insulin receptor (INSR). By binding to and activating INSR, it mimics the action of endogenous insulin to promote glucose uptake into cells and lower blood glucose levels. This mechanism supports its development for type 1 diabetes management.
Insulin Lispro 6 Day is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Eli Lilly is the sponsor responsible for the clinical development of this insulin lispro formulation.
Insulin Lispro 6 Day is in Phase 3 clinical development. It is an investigational product and has not been approved by the FDA or any other regulatory agency. The Phase 3 trial has been completed, and no active trials are currently listed.
Insulin Lispro 6 Day has been evaluated in one completed Phase 3 trial, NCT01134107, titled "Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use." This randomized, double-blind, active-controlled study enrolled 133 participants with type 1 diabetes across France, Germany, and Hungary.
Yes, Insulin Lispro 6 Day is also known as Insulin Lispro 6 Day (6D). The abbreviation 6D refers to the same investigational insulin lispro formulation developed by Eli Lilly and Company for type 1 diabetes pump therapy.